AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26506579
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy adapted for adolescents (CBT-A)
Trial: 23372142
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockade (CCB) - 60 mg oral nimodipine
Trial: 16646722
Drug: Verum acupuncture
RxNorm normalized name: Cinnamomum verum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verum acupuncture based on Traditional Chinese Medicine (TCM)
Trial: 14656278
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy (carboplatin or new drug)
Trial: 14656278
Drug: Platinum combination-based
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum combination-based therapy
Trial: 11505405
Drug: Single-agent carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single-agent carboplatin
Trial: 14656278
Drug: Single-agent new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent new drug
Trial: 11025952
Drug: Amrinone infusion
RxNorm normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amrinone infusion (17 patients)
Trial: 11025952
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion (15 patients)
Trial: 11025952
Drug: Olprinone infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olprinone infusion (14 patients)
Trial: 16306858
Drug: THC (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (10 mg)
Trial: 16306858
Drug: Cannabis extract
RxNorm normalized name: Cannabis sativa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis extract (10 mg THC + 5.4 mg CBD)
Trial: 1090905
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no group therapy)
Trial: 9140674
Drug: Nicardipine SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine SR (40‐80 mg for 21 months)
Trial: 9140674
Drug: Alacepril (25‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alacepril (25‐100 mg for 18 months)
Trial: 15538131
Drug: S-adenosyl-L-methionine
RxNorm normalized name: S-Adenosyl-L-Methionine (Sam-E)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosyl-L-methionine
Trial: 30685685
Drug: Three-drug combination
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug combination chemotherapy with methotrexate, doxorubicin, and cisplatin (standard chemotherapy)
Trial: 25851756
Drug: Weekly azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly azathioprine 300 mg pulse
Trial: 25851756
Drug: Daily azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily azathioprine 100 mg
Trial: 19318695
Drug: Intravenous tezosentan
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tezosentan at 0.2 mg/h for 24 hours followed by 1.0 mg/h for 24 hours (cohort I)
Trial: 19318695
Drug: Intravenous tezosentan
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tezosentan at 1.0 mg/h for 24 hours followed by 5.0 mg/h for 24 hours (cohort II)
Trial: 19318695
Drug: Intravenous tezosentan
RxNorm normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous tezosentan (cohort III)
Trial: 15576069
Drug: Combined metyrapone/low‐dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metyrapone/low‐dose dexamethasone test
Trial: 8066866
Drug: n‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA capsules (3.6 g)
Trial: 8066866
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (six capsules with a fat composition averaging the Danish diet)
Trial: 28982497
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel treatment for one year
Trial: 9787686
Drug: RSV‐IGIV, 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV‐IGIV, 750 mg/kg, monthly
Trial: 7664857
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 1 mg daily
Trial: 7664857
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 2 mg daily
Trial: 7664857
Drug: Budesonide, 1.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide, 1.6 mg daily
Trial: 2523772
Drug: nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide (100 mg x 2/day)
Trial: 2523772
Drug: phenylprenazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: phenylprenazone (200 mg x 2/day)
Trial: 1820675
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no injection)
Trial: 21277410
Drug: trivalent recombinant
RxNorm normalized name: INFLUENZA VACCINE,TRIVALENT RECOMBINANT (PF),VIL,0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trivalent recombinant hemagglutinin (rHA) vaccine, 45 μg HA/strain
Trial: 21277410
Drug: U.S. licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: U.S. licensed trivalent inactivated vaccine (TIV), 15 μg HA/strain
Trial: 21277410
Drug: trivalent recombinant
RxNorm normalized name: INFLUENZA VACCINE,TRIVALENT RECOMBINANT (PF),VIL,0.5ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trivalent recombinant hemagglutinin (rHA) vaccine
Trial: 18077012
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g Vit-C/day
Trial: 18077012
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g Vit-C/day
Trial: 16452740
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (1 mL of 10 mg/mL)
Trial: 16452740
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (1 mL of phosphate-buffered saline)
Trial: 30348219
Drug: Reading newspapers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading newspapers daily or infrequently
Trial: 27665206
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist treatment (e.g., warfarin)
Trial: 27665206
Drug: Hemoglobin >13.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoglobin >13.5 g/dl
Trial: 24642648
Drug: Vaginal lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal lactoferrin (LF) 300 mg administered 4 hours before amniocentesis
Trial: 24642648
Drug: Vaginal lactoferrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal lactoferrin (LF) 300 mg administered 12 hours before amniocentesis
Trial: 16267768
Drug: Single-dose sulfadoxine-pyrimethamine
RxNorm normalized name: pyrimethamine / sulfadoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose sulfadoxine-pyrimethamine (S-P)
Trial: 17460371
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg/day
Trial: 7756640
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithymocyte globulin (ATG) and cyclosporine (CsA) administered simultaneously for 4 days and 6 months respectively
Trial: 2147837
Drug: Enoximone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (1 mg/kg bolus followed by intravenous infusion of 5 to 10 micrograms/Kg/mn)
Trial: 29037641
Drug: Sham therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham therapy (SG)
Trial: 26527536
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day)
Trial: 23098762
Drug: onabotulinumtoxinA (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: onabotulinumtoxinA (all doses)
Trial: 10571630
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel at 4 degrees C
Trial: 10571630
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel at 40 degrees C
Trial: 10571630
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel at 22 degrees C (control group)
Trial: 6352001
Drug: Initial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial therapy directed at the poor-prognosis component of tumors
Trial: 28767271
Drug: TEAS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAS plus exercise therapy (TG)
Trial: 28767271
Drug: Sham TEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham TEAS plus exercise therapy (CG)
Trial: 26814294
Drug: ABT-639 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-639 (100 mg)
Trial: 31992495
Drug: Pregabalin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300 mg)
Trial: 28657703
Drug: Oral rinse
RxNorm normalized name: Oral Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rinse
Trial: 17421001
Drug: Whole-saliva and
RxNorm normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-saliva and oral-rinse samples
Trial: 7896982
Drug: Brief psychodynamic-interpersonal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief psychodynamic-interpersonal treatment
Trial: 7610222
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment
Trial: 582549
Drug: Lithium medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium medication (dosage: 24 mval/d to 36 mval/d)
Trial: 28397569
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (FLU‐IVIG)
Trial: 28397569
Drug: Collapsing categories
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collapsing categories with no treatment effect
Trial: 16877719
Drug: Arm 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1: Bolus FU in two 5-day cycles every 28 days before and after radiotherapy plus FU via protracted venous infusion (PVI) 225 mg/m2/d during XRT
Trial: 10971308
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg PSC (valspodar) as an i.v. infusion over 2 h
Trial: 10971308
Drug: Morphine HCl
RxNorm normalized name: morphine HCl
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine HCl (7.5 mg) infused over 2 h
Trial: 22370314
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and Cisplatin (GP) chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8; cisplatin 80 mg/m2 on day 1 every 3 weeks, for up to nine courses)
Trial: 12100939
Drug: Lanolin hand
RxNorm normalized name: Lanolin
DrugBank: Lanolin (DB11112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanolin hand cream
Trial: 9137929
Drug: Carbimazole +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole + Propranolol (40 mg)
Trial: 3298419
Drug: Pre-trial dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-trial dosage of cis(z)‐flupenthixol decanoate
Trial: 27209291
Drug: Oral lusutrombopag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lusutrombopag (14-day once-daily dosing)
Trial: 27209291
Drug: Oral lusutrombopag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lusutrombopag
Trial: 25311610
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg resveratrol capsule
Trial: 23602776
Drug: Rivaroxaban 2.5
RxNorm normalized name: rivaroxaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 2.5 mg twice-daily
Trial: 23602776
Drug: Rivaroxaban 5
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 5 mg twice-daily
Trial: 16636364
Drug: Horsechestnut seed
RxNorm normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horsechestnut seed extract therapy combined with conventional therapy
Trial: 10977025
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with insulin alone or with sulfonylurea (n = 75)
Trial: 10977025
Drug: Standard once-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard once-daily insulin injection (n = 78)
Trial: 10977025
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (n = 66)
Trial: 10977025
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (n = 70)
Trial: 8841900
Drug: Systemic tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic tetracycline (250 mg qds for 14 days)
Trial: 8841900
Drug: Modified Widman
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Widman flap surgery with adjunctive tetracycline
Trial: 29695594
Drug: Ofatumumab 3,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab 3, 30, or 60 mg every 12 weeks, or 60 mg every 4 weeks
Trial: 18390837
Drug: Ofatumumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofatumumab (all doses)
Trial: 25004803
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) (Control Group, CG) for 5 weeks
Trial: 22872468
Drug: Oral peptone
RxNorm normalized name: peptones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral peptone load (10 g)
Trial: 22872468
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium load (1 g)
Trial: 22872468
Drug: Oral peptone
RxNorm normalized name: peptones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral peptone load with aluminum hydroxide (AH)
Trial: 10997952
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (25 g CrH2O)
Trial: 9075670
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg terlipressin
Trial: 8566840
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg terlipressin
Trial: 8368169
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of nebulized solution of non-bronchodilator (+) isoprenaline
Trial: 3758469
Drug: HCT +
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCT + AMI (50 mg/5 mg)
Trial: 3758469
Drug: F +
RxNorm normalized name: Estroven Menopause Relief + Mood Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F + TRI (40 mg/50 mg)
Trial: 29722590
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 capsule (5,000 IU/day)
Trial: 26684633
Drug: Intra-articular TNF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular TNF blockers
Trial: 24857299
Drug: Tirofiban early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban early treatment group (administered routinely at ≥ 4 hours prior to angiography)
Trial: 24857299
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (tirofiban provisional administered during or after angiography)
Trial: 20059474
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review and counselling by a clinical pharmacist and clinical pharmacologist
Trial: 20059474
Drug: Usual routine
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual routine medication review in the ward
Trial: 20059474
Drug: Systematic medication
RxNorm normalized name: Integrase Inhibitors, antiinfectives for systematic use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic medication review and counselling
Trial: 12182234
Drug: Mud pack
RxNorm normalized name: Cream, Multi Ingredient Topical application Cream [3 ROSES FACIAL MUD PACK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mud pack treatment
Trial: 12182234
Drug: Thermal bath
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal bath treatment
Trial: 7579091
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 400 mg and a daily dose of 200 mg/day for 9 days (Group 1)
Trial: 7579091
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 200 mg and a maintenance dose of 100 mg/day for 9 days (Group 2)
Trial: 7579091
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 100 mg and a maintenance dose of 50 mg/day for 9 days (Group 3)
Trial: 7579091
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 200 mg and then 100 mg after each of four dialysis sessions (Group 4)
Trial: 1954179
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy followed by loco-regional treatment
Trial: 6800046
Drug: Phenoxymethylpenicillin 800
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 800 mg
Trial: 6800046
Drug: Azidocillin 750
RxNorm normalized name: azidocillin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azidocillin 750 mg
Trial: 6800046
Drug: Antibiotics (Phenoxymethylpenicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (Phenoxymethylpenicillin and Azidocillin)
Trial: 25635593
Drug: Norepinephrine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5 μg/ml
Trial: 25635593
Drug: Phenylephrine 100
RxNorm normalized name: phenylephrine 100 mcg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine 100 μg/ml
Trial: 21069355
Drug: Early feeding
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early feeding group (EFG) - oral liquid diet on the first postoperative day, advanced to regular diet within 24 hours as tolerated.
Trial: 21069355
Drug: Traditional care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional care group - nothing per orus until elimination of first flatus, then oral liquid diet followed by regular diet within 24 hours.
Trial: 18362558
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream application
Trial: 17413628
Drug: Cold application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold application and EMLA cream application
Trial: 10802893
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone acetate
Trial: 8820551
Drug: Judicially monitored
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Judicially monitored mental health treatment
Trial: 2860162
Drug: Povidone-iodine lubricating
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Povidone-iodine lubricating gel (PVP-I)
Trial: 31228090
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin Glargine
Trial: 26340704
Drug: Insulin Detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin Detemir